Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro does not list anger as a recognised side effect in its clinical trials or prescribing information, but some people do notice shifts in mood, irritability or emotional sensitivity, particularly in the early weeks. Whether those feelings are directly caused by tirzepatide, or driven by the physical changes that come with it, is the decision worth unpicking. As a prescription-only medicine, Mounjaro is subject to ongoing clinical review throughout treatment, and any persistent mood changes are worth raising with your prescriber.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest starting point is that tirzepatide's approved prescribing information (verified through the NHS tirzepatide medicines page and the eMC summary of product characteristics) does not list anger, irritability or mood changes among its recognised side effects. The large SURMOUNT-1 trial, which followed over 2,500 adults for 72 weeks, did not flag anger as a notable finding.
That said, people asking whether Mounjaro can make you angry are usually describing something real. The most likely explanation is indirect: the medicine's primary action is appetite suppression, and when you eat significantly less, blood glucose can dip more than usual between meals. That dip produces the irritability most of us recognise as being hungry, sometimes intensely so. It is a physiological response, not a personality change.
Nausea is also a frequent early companion to tirzepatide treatment, and feeling persistently queasy is, for most people, a reliable route to feeling short-tempered. Disrupted sleep (another effect some people notice when the GI side effects are at their worst) compounds things further. Once these early-weeks effects settle, which they typically do, the emotional roughness tends to settle with them.
A quick check worth doing: note whether the irritability peaks at a particular time of day, especially before a meal or several hours after eating. If it does, it almost certainly reflects your body adjusting to a lower calorie intake rather than anything intrinsic to the medicine.
Mounjaro carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional monitoring. This is routine for newer medicines and does not mean it is considered dangerous, but it does mean the regulator actively collects data on effects that were not prominent in pre-approval trials, including psychological ones.
There has been broader regulatory attention to mood and GLP-1 medicines across Europe and the US. The MHRA has reviewed the question and has not concluded that semaglutide or tirzepatide cause suicidal ideation or depression at rates above background, but the monitoring continues. You can read about how Mounjaro generally makes people feel beyond the side-effect list, which covers emotional wellbeing as well as physical sensations.
The Yellow Card reporting system exists precisely for signals like this. If you experience mood changes that feel out of character during Mounjaro treatment, reporting them at yellowcard.mhra.gov.uk contributes to the post-approval evidence base. It is not an admission that the medicine is to blame, it simply adds data.
Independently of anger specifically, low mood, anxious thoughts and in particular any thoughts of self-harm should always be escalated to your GP or prescriber quickly. They are not effects to monitor and wait on.
For most people who notice a bit of irritability in the first few weeks, the practical response is to look at whether they are eating enough protein, staying hydrated, and sleeping adequately alongside treatment. The NHS tirzepatide medicines page covers common effects and what warrants medical attention, it is a straightforward reference to bookmark.
Some people find that physical discomfort from treatment, whether that is muscle aches or fatigue, compounds emotional difficulty. Others notice that temperature sensitivity in the early weeks adds to a general sense of feeling off. These are patterns that tend to ease; they are worth noting, not ignoring.
The point where you should speak to a clinician rather than waiting it out: if the emotional changes are significant, persistent beyond the first few weeks, or include low mood, anxiety that interferes with daily life, or any thoughts of self-harm. Those fall outside the category of adjustment effects and deserve proper clinical assessment. You can also read about other unexpected effects some people attribute to Mounjaro, many of which similarly turn out to have an indirect explanation.
At nume, our prescribers review your treatment at every stage, not just at the start. If something does not feel right, that is what the aftercare team is there for, seven days a week. For anyone considering starting treatment and wanting to understand the full picture before committing, a free consultation with our prescribers is the natural first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.